Cosentyx (secukinumab) — United Healthcare
active ankylosing spondylitis
Initial criteria
- Diagnosis of active ankylosing spondylitis or active non-radiographic axial spondyloarthritis
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Simponi (golimumab), Rinvoq (upadacitinib), Taltz (ixekizumab), Xeljanz (tofacitinib)]
Reauthorization criteria
- Documentation of positive clinical response to Cosentyx therapy
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [same list as above]
Approval duration
12 months